Nektar reports positive top-line results from HAP study of NKTR-181 for chronic pain

US-based biopharmaceutical firm Nektar Therapeutics has reported positive top-line results from an oral human abuse potential (HAP) study of its opioid analgesic, NKTR-181, for chronic pain.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news